Here’s a glimpse into this hedge fund guru’s Q2 moves that reeled back in three biotech players.
Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) announced the reintroduction of the generic equivalent to Depo-Provera®1 …
Analyst says share weakness does not stem from encouraging news, but points to other underlying concerns.
Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) and Nuvelution Pharma are officially in collaboration for the development …
Though Teva shares took a hit upon the news, the analyst sees an upside to expectations in the distance.
Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) is saying goodbye to its remaining global women’s health …
Here’s why analysts are playing it cautiously optimistic on the struggling pharmaceutical giant.
A glimpse into OrbiMed Advisors’ recent moves in the healthcare space.
Analyst Louise Chen cheers that new Danish CEO means “good news” for Tesla investors.
How Do Biotech’s Movers and Shakers Fare Under Puravida Funds’ Healthcare-Centric Trading Strategy?